BioCentury
ARTICLE | Product Development

Novocure’s valuation tops $20B as it eyes shortened path to Optune’s label expansion in NSCLC

April 13, 2021 8:52 PM UTC

A DMC’s recommendation could shorten the path to a label expansion that would add a lung cancer indication for Novocure’s electric field therapy, which is already approved as Optune for two smaller indications.

The news boosted shares of both Novocure Ltd. (NASDAQ:NVCR) and partner Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688). Novocure touched an intraday all-time high of $218 before closing the day up $65.45 (50%) to $197.33 at a market cap over $20 billion.  Zai rose $29.24 (22%) to $161.29...

BCIQ Company Profiles

Novocure GmbH

Zai Lab Ltd.